NewAmsterdam Pharma Company (NAMS) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Study updates and timelines

• PREVAIL and BROADWAY studies are nearly identical in design, with PREVAIL's event rate at 12 months tracking in line with BROADWAY, which showed a 21% MACE benefit.

• An update on PREVAIL's overall timelines will be provided based on continued adjudication of events out to at least two years.

• The design paper for PREVAIL is expected to be published this year.

• Compliance in PREVAIL is being maintained through enhanced site visits and sharing positive LDL study results to motivate patients.

• Adverse events in completed LDL studies were lower on drug than placebo, supporting patient retention.

Drug profile and differentiation

• Obicetrapib, alone or with ezetimibe, enables 70%-80% of patients to reach risk-based goals with a convenient once-daily oral pill.

• The drug shows benefits beyond LDL reduction, including up to 50% reduction in Lp(a), elimination of small LDL particles, and reduced diabetes incidence.

• Recent data suggest a potential role in Alzheimer's disease prevention or treatment.

• The drug is positioned as highly differentiated, targeting multiple risk factors beyond LDL-C.

• No other drug in development matches its ability to reduce LDL particles by 80%-100%.

Market landscape and commercial strategy

• The market opportunity is large, with at least 30 million U.S. patients not at risk-based goals despite treatment.

• The commercial team has experience launching drugs in competitive markets and is confident in a successful launch.

• Approval in Europe is expected this year, with U.S. regulatory timelines to be provided mid-year.

• U.S. launch strategy is tied to having outcomes data public at launch, unlike Europe where pricing timelines differ.

• The presence of other oral options is seen as beneficial for raising disease awareness, not as direct competition.